Altan Pharma Acquires Injectables Maker GES
Altan Pharma Limited, an Irish specialty pharmaceutical company, has acquired a privately held group of Spanish companies, The GES Group. The GES Group develops, manufactures, and markets specialty injectable drugs. GES, headquartered in Spain, is comprised of three operating companies: GES GenÃ©ricos EspaÃ±oles Laboratorio, S.A.U., Genfarma Laboratorio, S.L. and Biomendi, S.A.U.
GES has been providing the Spanish hospital market with a injectable drugs since 1985. The company is a provider in the pain and anti-infective segments of the Spanish market and also has an international distribution network covering many European, Latin American, and Asian markets.
Malin Plc provided an equity investment of EUR 34.5 million ($38.5 million), and Altan also raised debt financing and additional equity financing for the transaction. Banco Sabadell provided the debt financing.
Source: Altan Pharma